AX 0601
Alternative Names: AX-0601Latest Information Update: 25 Apr 2023
Price :
$50 *
At a glance
- Originator ProQR Therapeutics
- Class Antihypoglycaemics; Obesity therapies; Oligonucleotides
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Obesity; Type 2 diabetes mellitus
Most Recent Events
- 18 Apr 2023 ProQR Therapeutics has patent protection for Axiomer® platform in China, Canada, Israel, New Zealand, Japan, Russia, South Africa, the US and Europe
- 05 Apr 2023 Early research in Obesity in Netherlands (Parenteral) (ProQR Therapeutics pipeline, April 2023)
- 05 Apr 2023 Early research in Type 2 diabetes mellitus in Netherlands (Parenteral) (ProQR Therapeutics pipeline, April 2023).)